poisar

Stock

Voyager Therapeutics, Inc. VYGR

$3.49+1.01%

Overview

VYGR market data

Price History

VYGR price chart · 3M
O
3.47
H
3.52
L
3.43
C
3.49
Vol
14,565.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$3.47
Previous Close
$3.46
Day High
$3.52
Day Low
$3.43
52 Week High
$4.46
52 Week Low
$2.94
7 Day Return
+5.12%
30 Day Return
+14.80%
90 Day Return
-9.82%
1 Year Return
-4.38%
Daily Notional Volume
$50.8K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.04
Diluted earnings per share over the trailing twelve months.
Beta
1.25
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-312.6%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.94 – $5.55
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $193.3M · P/B 1.11 · P/S 5.61.

Company News

6 captured
HC Wainwright & Co. Reiterates Buy on Voyager Therapeutics, Maintains $25 Price TargetBenzinga · Aug 10, 2026, 10:58 AM
Voyager Therapeutics Q2 EPS $(0.40) Beats $(0.48) Estimate, Sales $3.165M Miss $4.728M EstimateBenzinga · Aug 6, 2026, 10:03 PM
8-K filing — Voyager Therapeutics, Inc. (VYGR)SEC EDGAR · Jul 13, 2026, 12:44 PM
Voyager Therapeutics Presents Six‑Month Toxicology Data At AAIC Showing Investigational Alzheimer’s Gene Therapy VY1706 Was Well Tolerated And Cut Tau Protein Up To 75% In PrimatesBenzinga · Jul 13, 2026, 12:10 PM
Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial StockBenzinga · Jul 1, 2026, 11:55 AM
Voyager Therapeutics Issued FDA Clearance For Its Investigational New Drug Application For VY1706 To Treat Alzheimer's DiseaseBenzinga · Jun 1, 2026, 12:02 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock